Follow the Pundits
Tag: Funanc1al Investing
ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?
Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?
Lionsgate Studios: Insiders Are Buying. Should the Stock Get the Lion's Share of Your Portfolio?
🦁 Liberty 77 Capital, led by ex-Treasury Secretary Steven Mnuchin, bought over 8 million shares of Lionsgate Studios (NYSE: LION). Revenues are up, insiders are bullish, and the studio is freshly split from Starz. Is it showtime—or a risky sequel?
John Paulson Is Loading Up on Perpetua Resources. Should You?
John Paulson knows a good discount when he sees one—and he just grabbed another $100M worth of Perpetua Resources (PPTA). But what is this gold-and-antimony play really about? From Idaho mines to strategic minerals and a wink at squirrel invasions, we break it all down.
Bausch Health: Paulson Doubles Down, Stock Breaks Out, Recovery Accelerates
Bausch Health ($BHC) is back in the spotlight as legendary investor John Paulson adds millions more in shares, fueling a breakout rally. With Q2 earnings showing revenue growth, profit rebound, and debt repayment plans, could BHC be staging its long-awaited comeback?
Apple Remains Warren Buffett’s Top Stock — Should You Still Bite?
Buffett’s got $60 billion riding on Apple. Services are booming. iPhone addiction remains. But is it still worth your bite — or should you wait for a sweeter dip? 🍏🤔
Daniel Loeb Still Thinks PG&E Stands for Purchase, Grab & Enjoy
PG&E has gone from fiery headlines to financial footing—and Daniel Loeb’s Third Point is all-in. With 14% of his portfolio riding on PCG, a growing customer base, and wildfire risks contained (for now), is this survivor stock worth a second look?
2 comments
|
Warren Buffett’s Berkshire Hathaway and Renaissance Like Verisign. Should You Register Too?
Berkshire bought big. Renaissance holds strong. Is Verisign (VRSN) a quiet winner—or is the best already priced in? Let’s decode the signals.
Can Robinhood Steal the Show and Make All Richer? Renaissance Answers Yes!
Robinhood is no longer just a meme darling—it’s a fintech juggernaut turning heads at Renaissance Technologies. With revenue surging 50% and net income up 114%, it might be stealing more than hearts. Is HOOD still a buy? Dive into the numbers, institutional backing, and a few emoji-laced insights. 🏹💸
If Madison Square Garden Entertainment Keeps John Rogers Entertained, Maybe You Should Grab a Seat Too
MSGE isn’t just concerts and Christmas Spectaculars—it’s quietly profitable, backed by top funds, and has the attention of Ariel Investments’ John Rogers. But is the show just starting—or already halfway through?
CAE Inc. (NYSE: CAE) – Flying High and Simulating Higher
From flight simulators to defense training, CAE is flying high in Charles Brandes's portfolio. Here's why this stock might just land a spot in yours.